AgingResearch.NewsJoin free

TGF-beta1 neutralizing antibody

TGF-beta1 neutralizing antibody has been studied in 1 paper since 2022: 1 observational study in people. The newest paper, Jul 14, 2022: “Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality”.

Intervention

1 paper studies it2 findingsUpdated

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

  • 2 independent labs in 2 countries
  • Funders: Japan Society for the Promotion of Science and 5 more
  • Humans1

What did studies of TGF-beta1 neutralizing antibody find?

2

Studies of TGF-beta1 neutralizing antibody measured 2 outcomes; the most studied are Ki67+ cells (1 study) and cardiac function (1).

Ki67+ cells

downin human cells1

1 study

  1. TGF-beta1 neutralizing antibody decreases Ki67+ cells in human cells.

    “TGF-β1 neutralising antibody reduced the number of Ki67-positive proliferative cells”

    Cellsin 3D-engineered skin culture

    Platelet lysate can support the development of a 3D-engineered skin for clinical application

    Cell and tissue research

More on Ki67+ cells

Cardiac function

upin mice1

1 study

  1. TGF-beta1 neutralizing antibody improves cardiac function in mice.

    “treatment with a transforming growth factor β1-neutralizing antibody ameliorated cardiac dysfunction in mLOY mice”

    Animalsin mLOY miceheartmales

    Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality

    Science (New York, N.Y.)

Latest

Related